Skip to main content
Premium Trial:

Request an Annual Quote

Pathwork Diagnostics, Novartis Team Up for Cancer Biomarker Discovery

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer molecular diagnostics developer Pathwork Diagnostics announced today a collaboration with Novartis for the discovery of cancer biomarkers.

The biomarkers will be used as a basis for diagnostics "across a range of cancer types," the Redwood City, Calif.-based firm said in a statement.

Under the terms of the deal, both companies have the rights to develop and commercialize the diagnostic products. Further terms were not disclosed.

Last month Pathwork Diagnostics received clearance from the US Food and Drug Administration for use of its microarray-based Tissue of Origin test with formalin-fixed embedded tissue.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.